1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||
a)
|
Name
|
Ms E Walmsley
| |
b)
|
Position/status
|
Chief Executive Officer
| |
c)
|
Initial notification/ amendment
|
Initial notification
| |
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
a)
|
Name
|
GSK plc
| |
b)
|
LEI
|
5493000HZTVUYLO1D793
| |
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||
a)
|
Description of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
| |
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| |
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
£13.2260
|
7,963.086
| ||
d)
|
Aggregated information
Aggregated volume
Price
|
N/A (single transaction)
| |
e)
|
Date of the transaction
|
2022-10-10
| |
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr I Mackay
| |||
b)
|
Position/status
|
Chief Financial Officer
| |||
c)
|
Initial notification/ amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GSK plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.2260
|
1,917.266
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2022-10-10
| |||
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
GSK plc published this content on 12 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2022 11:41:02 UTC.